MedTrace Logo

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-11-29

Study results available
· View outcomes & findings →

Summary

This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.

Conditions

  • Infections, Intestinal

Interventions

DRUG

Drug: GSK2251052

Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

DRUG

Meropenem

Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion

OTHER

Placebo

saline placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-03
Primary Completion
2012-03-05
Completion
2012-03-05

Countries

  • United States
  • Canada
  • Czechia
  • France
  • Italy
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381562 on ClinicalTrials.gov